ZURA BIO LIMITED Defined Contribution Plan, Cost
ZURA BIO LIMITED (ZURA) reported Defined Contribution Plan, Cost of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-08-11
- ZURA BIO LIMITED defined contribution plan, cost for the quarter ending 2026-06-30 was $200.00K, a 100.00% increase year-over-year.
- ZURA BIO LIMITED defined contribution plan, cost for the quarter ending 2026-03-31 was $200.00K, a 100.00% increase year-over-year.
- ZURA BIO LIMITED defined contribution plan, cost for the quarter ending 2025-12-31 was $100.00K, a 0.00% change year-over-year.
- ZURA BIO LIMITED defined contribution plan, cost for the quarter ending 2025-09-30 was $100.00K, a 75.44% increase year-over-year.
- ZURA BIO LIMITED defined contribution plan, cost for fiscal 2025 was $500.00K, a 66.67% increase from fiscal 2024.
- ZURA BIO LIMITED defined contribution plan, cost for fiscal 2024 was $300.00K, a 200.00% increase from fiscal 2023.
- ZURA BIO LIMITED defined contribution plan, cost for fiscal 2023 was $100.00K.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 6 month as first filed | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-11 | $400.00K 10-Q · filed 2026-08-11 | $500.00K derived: sum of 3 quarters · filed 2026-08-11 | $600.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-07 | $300.00K derived: sum of 2 quarters · filed 2026-05-07 | $400.00K derived: sum of 3 quarters · filed 2026-05-07 | $500.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $200.00K derived: sum of 2 quarters · filed 2026-03-19 | $300.00K derived: sum of 3 quarters · filed 2026-08-11 | $500.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-13 | $200.00K derived: sum of 2 quarters · filed 2026-08-11 | $400.00K 10-Q · filed 2025-11-13 | $400.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-11 | $0.20 10-Q · filed 2026-08-11 | $200.00K 10-Q · filed 2025-08-14 | $300.00K derived: sum of 3 quarters · filed 2026-08-11 | $357.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-07 | $200.00K derived: sum of 2 quarters · filed 2026-05-07 | $257.00K derived: sum of 3 quarters · filed 2026-05-07 | $298.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $157.00K derived: sum of 2 quarters · filed 2026-03-19 | $198.00K derived: sum of 3 quarters · filed 2026-03-19 | $300.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | $57.00K 10-Q · filed 2025-11-13 | $98.00K derived: sum of 2 quarters · filed 2025-11-13 | $200.00K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $41.00K 10-Q · filed 2025-08-14 | $100.00K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | $100.00K 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |